- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Coalition of Leading Cancer Centers Aims to Improve Personalized Treatment
"The growth of ORIEN coincides with President Obama's announcement and the recognition that molecularly targeted medicine holds tremendous promise for all disease, particularly cancer," said Michael Caligiuri, MD, director of The Ohio State University Comprehensive Cancer Center and CEO of the James Cancer Hospital and Solove Research Institute.
(OSUCCC-James)
A novel research partnership anchored by two of North America’s leading cancer centers, Moffitt Cancer Center and The Ohio State University Comprehensive Cancer Center — Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, today announced the addition of four nationally recognized cancer centers, bringing its membership to six and extending the national oncology network from coast to coast.
The new members of the Oncology Research Information Exchange Network (ORIEN) include:
- City of Hope
- University of Virginia Cancer Center (UVA)
- University of Colorado Cancer Center
- University of New Mexico Cancer Center (UNMCC)
The addition of the new ORIEN members is expected to exponentially increase the number of patients consenting to donate their tissue and clinical data — including corresponding genomic data – for research to understand cancer at the molecular level, with the goal of developing more targeted cancer treatments.
Read the complete press release:
Source: Moffitt Cancer Center website
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Trastuzumab Deruxtecan Receives FDA Approval for HER2-Positive Solid Tumors
April 5th 2024FDA granted accelerated approval to trastuzumab deruxtecan-nxki for adult patients with unresectable or metastatic HER2-positive solid tumors who received prior systemic treatment and have no satisfactory alternative treatment options.
Read More
